Ascorbyl Palmitate: A Comprehensive Reference
1. Identity and Chemical Characterization
Chemical Names and Identifiers
Ascorbyl palmitate (AscP) is a lipophilic derivative of ascorbic acid (vitamin C).
The structure of ascorbyl palmitate features an ester bond located at the 6-position of ascorbic acid.
Accordingly, its systematic and common synonyms include L-ascorbic acid 6-palmitate, 6-O-palmitoyl-L-ascorbic acid, ascorbyl-6-palmitate, 6-monopalmitoyl-L-ascorbate, palmitoyl ascorbate, and vitamin C palmitate.
In the EINECS registry it carries the number 205-305-4, and its CAS Registry Number is 137-66-6.
In the European Union it is designated as food additive E 304(i).
From a chemistry standpoint, the PubChem compound record for ascorbyl palmitate identifies it as C22H38O7 and describes it as an ester formed from ascorbic acid and palmitic acid.
Within the ascorbyl palmitate structure, an acidic group (C3–OH group) with a pKa value of 4.2 exists, which is relevant to its pH-dependent behavior in biological and food matrices.
Ascorbic acid is not fat-soluble but ascorbyl palmitate is, thus combining them produces a fat-soluble antioxidant; it exists as a white or yellowish-white powder of citrus-like odor.
Natural Source and Commercial Origin
Ascorbyl palmitate is derived from corn dextrose fermentation and palm oil.
However, although its two parent components — ascorbic acid and palmitic acid — are naturally occurring, ascorbyl palmitate is manufactured by chemical processes; it is not created by natural biological pathways.
It is prepared synthetically by the reaction of ascorbic acid with sulfuric acid followed by reesterification with palmitic acid.
Ascorbyl palmitate is typically synthesized using two primary methods: the chemical process and the enzymatic process. The chemical process is the most commonly employed method for the production of ascorbyl palmitate; the traditional esterification process of ascorbic acid with palmitic acid involves several steps.
It is produced through an esterification process involving ascorbic acid and palmitic acid, either in the presence of enzyme lipase (immobilized) or with sulfuric acid as a catalyst.
Common Forms and Preparations
Ascorbyl palmitate is commercially available in several forms:
- Powder / bulk ingredient: Used as a food preservative and antioxidant additive in oils, fats, bakery products, and fat-containing foods.
- Oral dietary supplement capsules/tablets: The presence of ascorbyl palmitate in oral supplements contributes to the ascorbic acid content of the supplement and probably helps protect fat-soluble antioxidants.
- Topical cosmetic preparations: It is also used as a preservative and an antioxidant in cosmetic creams and lotions to prevent rancidity.
- Nanoformulations: Ascorbyl palmitate is a highly bioavailable, fat-soluble form of ascorbic acid; to enhance its chemical stability, ascorbyl palmitate has been processed as a nanosuspension using high-pressure homogenization (HPH) techniques using sodium dodecyl sulfate and polysorbate 80 as stabilizers.
- Lipid-matrix delivery systems: A new technological matrix (Lipomatrix) based on a molten fats core in which ascorbyl palmitate is embedded is able to deliver lipophilic compounds in a well-dispersed and emulsified form once exposed to duodenal fluids.
Ascorbyl palmitate is used in well over a thousand cosmetic formulations at low concentrations; ascorbyl palmitate is used in cosmetics at concentrations between 0.01 and 0.2%.
2. Historical and Traditional Use
Ascorbyl palmitate does not have roots in traditional herbalism or ancient medicinal practice, as it is a fully synthetic compound created by 20th-century industrial chemistry. Its history is entirely within the modern food science and pharmaceutical era.
Lloyd A. Hall is often credited with identifying the oxidative process in lipid-containing foods, leading to the discovery and identification of various antioxidants that are still widely used today for stabilizing oils and fats, such as lecithin, ascorbyl palmitate, and citric acid. Dr. Albert Szent-Györgyi is renowned for his discovery of ascorbic acid and its antioxidant properties, a breakthrough that greatly influenced the use of antioxidants in various industries.
Ascorbyl palmitate was first commercially utilized in the 1960s as an antioxidant in the food and beverage as well as pharmaceutical sectors. Since then, numerous studies have been conducted on the synthesis, properties, and applications of ascorbyl palmitate.
Its primary historical application was the stabilization of fats and oils against oxidative rancidity — an industrial food-technology use rather than a therapeutic one. Its role as a dietary supplement and cosmetic active emerged later, in the 1980s and 1990s, following greater interest in lipophilic antioxidants and vitamin C chemistry.
In 1998, the European Union's Scientific Committee on Food (SCF) considered the use of ascorbyl palmitate as antioxidant in infant formulae and follow-on formulae as acceptable for healthy infants and young children at levels up to 10 mg/L in infant formulae and at corresponding levels in food for special medical purposes for the same age group.
3. Key Constituents, Active Compounds, and Mechanisms of Action
Chemical Identity and the Dual-Phase Nature
Chemically, ascorbyl palmitate is an ester of ascorbic acid and palmitic acid and is commonly treated as a lipid-compatible form of vitamin C rather than a standard water-phase vitamin.
This dual nature — combining a hydrophilic ascorbate moiety with a lipophilic 16-carbon fatty acid chain — gives it surface-active (amphipathic) properties that allow it to position itself at oil-water interfaces, within lipid bilayers, and on cell membrane surfaces. This distinguishes its antioxidant geometry from either pure ascorbic acid (water-phase) or pure tocopherol (membrane interior).
Free Radical Scavenging
The hydroxyl free radical (OH•) scavenging properties of ascorbyl palmitate were tested in various systems; the inhibition of polymerization of bovine serum albumin by OH• free radicals generated by the Fenton reaction indicated ascorbyl palmitate exerts a considerable protective effect against polymerization by scavenging the OH• free radicals.
The compound disperses in biomembranes, where it retains the potent antioxidant properties of ascorbate. An in vitro electron spin resonance study with human blood loaded with equimolar concentrations of ascorbyl palmitate and ascorbic acid showed that ascorbyl palmitate generates the ascorbyl radical signal the way ascorbic acid does, in terms of the signal's shape, location, and increased amplitude with increasing concentrations.
Tocopherol Regeneration and Synergistic Antioxidant Activity
One of the most well-documented mechanistic properties of ascorbyl palmitate is its ability to regenerate α-tocopherol (vitamin E) after it has been oxidized by free radicals.
The mechanism of the synergistic antioxidant effect of ascorbyl palmitate and α-tocopherol was investigated in ethyl linoleate model and sunflower oil systems. The mixture was stabilized through continuous regeneration of α-tocopherol from its oxidation product α-tocopherylquinone. This reaction is catalyzed by acids and proceeded through the formation of the α-tocopherone ion as an intermediate product. In addition to the direct reduction of this intermediate by ascorbyl palmitate, phosphatidylethanolamine can also cause regeneration indirectly by reacting with dehydroascorbyl palmitate or other tricarbonyl compounds to form amino reductones.
In cooked, minced turkey meat, a combined strategy using natural antioxidants including ascorbyl palmitate was tested. Tocopherols at 200 ppm each significantly reduced lipid oxidation during nine days of cold storage, measured as thiobarbituric acid-reactive substances (TBARS). Synergism between the two antioxidants was demonstrated as an increasing relative reduction in TBARS values over time when both antioxidants were added. This synergism depended on the availability of oxygen and was most significant for atmospheric packaging.
Thermodynamic analysis showed that the Gibbs free energy (ΔG) for the regeneration reactions of α-, γ-, and δ-tocopherol by ascorbyl palmitate were −1.019, −9.482, and −18.151 kJ/mol respectively, indicating that ascorbyl palmitate was prone most favorably to regenerate δ-tocopherol, with this combination exhibiting the highest antioxidant abilities.
Membrane-Level Antioxidant Protection (Erythrocyte Model)
Research sought to determine whether the amphipathic derivative of ascorbate, ascorbate 6-palmitate, is retained in the cell membrane of intact erythrocytes and whether it helps to protect the cells against peroxidative damage. Ascorbate 6-palmitate binding to erythrocytes was found to be dose-dependent, and the derivative was retained during multiple wash steps required for preparation of ghost membranes. It remained on the extracellular surface of the cells, because it was susceptible to oxidation or removal by cell-impermeant agents. When bound to the surface of erythrocytes, ascorbate 6-palmitate reduced ferricyanide, an effect associated with generation of an ascorbyl free radical signal on EPR spectroscopy.
Erythrocyte-bound ascorbate 6-palmitate protected membrane α-tocopherol from oxidation by both ferricyanide and a water-soluble free radical initiator, suggesting that the derivative either reacted directly with the exogenously added oxidant, or that it was able to recycle the α-tocopheroxyl radical to α-tocopherol in the cell membrane. Ascorbate 6-palmitate also partially protected cis-parinaric acid from oxidation when this fluorescent fatty acid was intercalated into the membrane of intact cells. These results show that an amphipathic ascorbate derivative is retained on the exterior cell surface of human erythrocytes, where it helps to protect the membrane from oxidant damage originating outside the cells.
Importantly, when incorporated into the cell membranes of human red blood cells, ascorbyl palmitate has been found to protect them from oxidative damage and to protect α-tocopherol from oxidation by free radicals; however, the protective effects of ascorbyl palmitate on cell membranes have only been demonstrated in the test tube.
NLRP3 Inflammasome Inhibition
The aberrant activation of the NLRP3 inflammasome contributes to pathogenesis of multiple inflammation-driven human diseases, and medications targeting NLRP3 inflammasome are not yet approved for clinical use. Research has shown that ascorbyl palmitate (AP), a lipophilic derivative of ascorbic acid and a safe food additive, is a potent inhibitor of NLRP3 inflammasome. Compared with ascorbic acid, AP inhibited the activation of NLRP3 inflammasome with increased potency and specificity.
The mechanism involves direct scavenging of mitochondrial reactive oxygen species (mitoROS) by its antioxidant activity; animal experiments demonstrated ascorbyl palmitate attenuated LPS-induced systemic inflammation, DSS-induced colitis and experimental autoimmune encephalomyelitis (EAE). These findings were in preclinical (in vitro and mouse) models, not human clinical trials.
Lipid Peroxidation Inhibition in Foods
Ascorbyl palmitate at 0.01% reduces the rate of autoxidation of soybean, safflower, sunflower, peanut, and corn oil.
Ascorbyl palmitate is an orally active ester formed from ascorbic acid and palmitic acid, used as an antioxidant and food additive. In preventing fat and oil oxidation it is more efficient than butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT).
4. Bioavailability and Metabolic Fate
The question of whether ascorbyl palmitate reaches systemic circulation as an intact molecule or is hydrolyzed before absorption is critical to understanding its biological effects after oral administration.
Taking ascorbyl palmitate orally probably does not result in any significant incorporation into cell membranes because most of it appears to be hydrolyzed (broken apart into palmitate and ascorbic acid) in the human digestive tract before it is absorbed. The ascorbic acid released by the hydrolysis of ascorbyl palmitate appears to be as bioavailable as ascorbic acid alone.
The EFSA 2015 safety assessment reached a similar conclusion: biological data on ascorbyl palmitate are sparse and the safety assessment of it for use as a food additive is mainly based on the assumption that ascorbyl palmitate fully hydrolyses pre-systemically to ascorbic acid and its respective fatty acid.
This was supported by an in vitro study reporting near-complete hydrolysis of ascorbyl palmitate in simulated intestinal fluid and by human data. The Panel considered that the toxicity of ascorbyl palmitate can be extrapolated from data describing the toxicity of ascorbic acid and palmitic acid.
Notably, behavior in the brain may differ from the gut. When injected into the internal carotid artery, ascorbyl palmitate penetrated the blood-brain barrier and was principally retained in brain tissue as an intact molecule. However, the analytical method used (thin-layer chromatography) was qualitative and no conclusion could be drawn about the precise amount that crossed the barrier or the fraction that underwent hydrolysis in the brain.
Studies investigating ascorbyl palmitate as a carrier of ascorbate into neural tissue found that ascorbate was recovered from cerebral cortex and carotid body tissues; its content was higher in both tissues, by nearly an order of magnitude, after ingestion of ascorbyl palmitate than after ingestion of ascorbic acid, and the ascorbate level was higher in the carotid body than in the cortex. These animal-model results require confirmation in controlled human studies.
5. Scientific Evidence by Area of Use
5.1 Food Preservation and Antioxidant Stabilization
Evidence: Strong (established industrial/food science evidence)
The antioxidant function of ascorbyl palmitate in fat-containing foods and cosmetics is the best-established and most extensively studied area of its use. In the processing industry, it is widely used as a safe additive and preservative, primarily as an antioxidant for lipids to prevent rancidity in foods containing fats and oils.
It acts synergistically with alpha-tocopherol in oils and fats.
This use is backed by decades of food-science research, industrial application data, and regulatory review by both the FDA and EFSA.
5.2 Skin Health and Cosmetic Applications
Evidence: Preliminary to moderate; limited controlled human trials; some conflicting signals
L-ascorbic acid and its derivatives including ascorbyl palmitate are basic ingredients in anti-aging products due to their potent antioxidant activities and photoprotective properties and their involvement in collagen biosynthesis.
Collagen synthesis: An in vitro study on human foreskin fibroblast cultures demonstrated that ascorbyl palmitate can stimulate collagen synthesis at concentrations between 5 and 20 μM, i.e. at lower doses than ascorbic acid.
This level of production was comparable to that obtained with 100 μM of ascorbic acid; cells treated with 10 μM 6-O-palmitoyl ascorbate for 36 hours showed a collagen production three times higher than that observed with 10 μM vitamin C.
This is in vitro evidence only; robust controlled human clinical trials specifically isolating the collagen-promoting effect of ascorbyl palmitate have not been published.
Photoprotection: A review in the Journal of Clinical and Aesthetic Dermatology detailed the main mechanisms of action and clinical applications of topical vitamin C on the skin. As one of the most powerful antioxidants in the skin, vitamin C has been shown to protect against photoaging, ultraviolet-induced immunosuppression, and photocarcinogenesis. These effects relate to ascorbic acid derivatives broadly; evidence specific to ascorbyl palmitate's topical photoprotection in controlled human trials remains limited.
Conflicting UV evidence: Two different studies found that ascorbyl palmitate did not protect mouse skin from UVB-induced photoaging, and may also promote UVB-induced lipid peroxidation and cytotoxicity in human keratinocytes, which consequently exacerbates skin damage.
A review of ascorbyl-6-palmitate in comparison to L-ascorbic acid noted that studies have shown the former to be toxic to keratinocytes in the presence of UVB; its esterification is different from most esters in that the esterification occurs at a side chain (C6) instead of the active center.
These findings introduce an important caveat about topical ascorbyl palmitate in sun-exposed or UV contexts and remain an active area of discussion.
Anti-inflammatory in skin: Some clinical studies suggest that ascorbyl palmitate possesses anti-inflammatory activity and exhibits possible beneficial effects in treating some inflammatory dermatoses, though the number and scale of such human clinical studies is small.
Skin penetration and delivery: Investigating ascorbyl palmitate skin permeation from microemulsions, researchers reported that the effectiveness of this antioxidant after topical application was dependent on both its concentration in the vehicle and the type of microemulsion.
Hyperpigmentation: Although ascorbyl palmitate has been shown to potentially exert a lightening and anti-melanogenic effect — attributed to its antioxidant activity — current evidence remains limited, requiring further research to confirm the specific efficacy of ascorbyl palmitate.
5.3 Erythrocyte and Cardiovascular Antioxidant Protection
Evidence: In vitro only; no confirmed human clinical trials
The erythrocyte membrane protection studies by Ross, Mendiratta, May, and colleagues (Vanderbilt University, 1999) are the most cited mechanistic human-cell studies. Ascorbate 6-palmitate binding to erythrocytes was dose-dependent and was retained on the membrane. When bound to the surface of erythrocytes, ascorbate 6-palmitate reduced ferricyanide, an effect associated with generation of an ascorbyl free radical signal on EPR spectroscopy. Erythrocyte-bound ascorbate 6-palmitate protected membrane α-tocopherol from oxidation by both ferricyanide and a water-soluble free radical initiator, suggesting that the derivative either reacted directly with the exogenously added oxidant or was able to recycle the α-tocopheroxyl radical to α-tocopherol in the cell membrane.
However, as noted by the Linus Pauling Institute, the protective effects of ascorbyl palmitate on cell membranes have only been demonstrated in the test tube; taking ascorbyl palmitate orally probably does not result in any significant incorporation into cell membranes because most of it appears to be hydrolyzed in the human digestive tract before it is absorbed.
Ascorbyl palmitate acts as an antioxidant bioactive substance with therapeutic effects in some diseases related to oxidative stress, such as anemia, atherosclerosis, and hyperuricemia, but these are preliminary or mechanistic claims, not established by human clinical trials.
5.4 Inflammation and Immune Modulation
Evidence: Preclinical (in vitro and animal models only); no human clinical trials
A 2024 study published in International Immunopharmacology (Zhang et al.) established ascorbyl palmitate as a potent inhibitor of the NLRP3 inflammasome:
Ascorbyl palmitate has stronger inhibitory effects on NLRP3 inflammasome than ascorbic acid; it specifically inhibits NLRP3 inflammasome activation; it inhibits NLRP3 inflammasome activation via scavenging mitochondrial ROS; and it attenuated LPS-induced systemic inflammation, DSS-induced colitis, and experimental autoimmune encephalomyelitis in animal models.
All of these experiments were performed in cell culture and mouse models. Translation to human clinical outcomes has not been demonstrated.
5.5 Oncology / Antiproliferative Activity
Evidence: In vitro and animal studies only; no human clinical evidence
Multiple in vitro studies have demonstrated antiproliferative and pro-apoptotic activity of ascorbyl palmitate against cancer cell lines:
- HER2-positive breast cancer: A study explored in vitro dual treatment using ascorbyl palmitate and trastuzumab in HER2-positive SK-BR-3 BC cells. Ascorbyl palmitate reduced cell viability in a time- and dose-dependent manner, and its combination with trastuzumab further decreased cell viability. A cytometric analysis showed enhanced apoptosis after combination treatment; mRNA analysis revealed upregulated TP53 mRNA expression, along with upregulation of BAX, CYCS, CASP3, and CASP8 gene expression, while BCL-2 and BCL2L1 genes were downregulated.
- Melanoma (in vivo mouse model): A dual drug delivery system was developed to encapsulate ascorbyl palmitate and paclitaxel for synergistic cancer therapy; they were incorporated into solid lipid nanoparticles which were used to treat murine B16F10 melanoma that had metastasized to the lungs of mice. In vitro cytotoxicity assays indicated that the AP/PTX-SLNs with an AP/PTX mass ratio of 2/1 provided the optimal synergistic anticancer efficacy.
- Ehrlich ascites carcinoma (mouse model): Combined treatment with nanoformulated ascorbyl palmitate significantly reduced tumor growth, augmented the antioxidant status, extremely reduced lipid peroxidation, induced cell cycle arrest at G2/M phase and apoptosis, showed significant inhibition of the IL-6/STAT3 signaling pathway, and inhibited angiogenesis and metastasis via downregulation of VEGF and MMP9.
The existing data about the applications of ascorbyl palmitate in promoting human health is still lacking. No human clinical trials have been completed or reported investigating ascorbyl palmitate as an anticancer agent. All findings remain at the preclinical level.
5.6 Neural Tissue and Neuroprotection
Evidence: Animal studies only; mechanistically interesting but unproven in humans
Researchers investigated the hypothesis that ascorbyl-6-palmitate could serve as a carrier of ascorbate into neural tissues, where ascorbate could exert its physiological effects in the biomembranes that are the target sites of cellular signaling pathways which are normally hardly accessible to the water-soluble compound. The major objective was to determine whether ascorbate could be recovered from cerebral cortex and carotid body tissues, both sensitive to the hypoxic stimulus, after ascorbyl palmitate was given by gavage.
Hypoxia decreased the ascorbate content which implies physiological activity of ascorbate carried alongside the ascorbyl palmitate molecule. The lipophilic ascorbyl palmitate was able to cross biological barriers and satisfied the tissue demand for ascorbate better than the hydrophilic form. Ascorbyl palmitate has been considered as the preferred form of transport of ascorbate into neural tissues based on these animal studies, which have yet to be replicated in humans.
5.7 Formulation as a Drug Delivery Vehicle
Evidence: Emerging preclinical research
A co-loaded drug delivery system based on ascorbyl palmitate that can transport various functional drugs to their targets within a tumor represents an attractive strategy for increasing the efficiency of anticancer treatment. Beyond oncology, a novel technological matrix based on a molten fats core in which ascorbyl palmitate is embedded was shown to deliver lipophilic compounds in a well-dispersed and emulsified form once exposed to duodenal fluids; authors described and quantified improved bioaccessibility, enteric absorption and efficacy compared with non-formulated commercial products using in vitro models of human intestine and prostatic tissue.
6. Body Systems and Health Areas Associated with Ascorbyl Palmitate
- Cardiovascular / Hematologic system: Erythrocyte membrane protection (in vitro); antioxidant defense against lipid peroxidation in plasma lipoproteins (primarily mechanistic evidence).
- Immune / Inflammatory system: NLRP3 inflammasome inhibition; reduction of pro-inflammatory cytokine IL-1β production (preclinical animal models).
- Integumentary system (skin): Topical antioxidant and photoprotectant; collagen biosynthesis stimulation; anti-aging and anti-hyperpigmentation (limited clinical data; some conflicting UV evidence).
- Central nervous system: Potential delivery vehicle for ascorbate across the blood-brain barrier (animal data only).
- Oncology: Antiproliferative and pro-apoptotic activity in multiple cancer cell lines (in vitro and animal models only).
- Gastrointestinal / food matrix: Prevents oxidative rancidity in dietary fat-containing foods; established and regulatory-approved use.
Some evidence suggests its possible application in gastroenterology, immunology, cardiology, and skin care, though clinical human evidence across most of these domains remains limited or absent.
7. Dosage Forms and Dosages Reported in Studies
The following dosages and forms appear in the published literature. They are reported here as found in sources and do not represent clinical recommendations.
- Food additive use: Ascorbyl palmitate is used in peanut oil at a maximum level of 200 mg/kg individually or in combination. The FDA standard of identity for margarine permits ascorbyl palmitate as an optional ingredient allowed as a preservative at up to 0.02% by weight of the finished product.
- Regulatory ADI / RDA: The recommended daily allowance (RDA) of ascorbyl palmitate, according to the World Health Organization and the Joint Food and Agricultural Organization, is 1.25 mg/kg per day. The European Food Safety Authority (EFSA) evaluated ascorbyl palmitate and established an Acceptable Daily Intake (ADI) of 5 mg/kg body weight per day.
- In vitro collagen synthesis studies: Collagen synthesis was stimulated at concentrations between 5 and 20 μM in human foreskin fibroblast cultures.
- In vitro anti-cancer studies (HER2-positive breast cancer): The study used HER2-positive SK-BR-3 BC cells treated with ascorbyl palmitate, trastuzumab, or their combination; ascorbyl palmitate reduced cell viability in a time- and dose-dependent manner.
- Cosmetic / topical formulations: Ascorbyl palmitate is used in cosmetic preparations at concentrations between 0.01% and 0.2%.
- Infant formula: Ascorbyl palmitate was considered acceptable at levels up to 10 mg/L in infant formulae.
8. Safety Considerations and Interactions
Regulatory Safety Status
Ascorbyl palmitate has been granted Generally Recognized as Safe (GRAS) status by the FDA in the United States and is listed in the Everything Added to Food in the United States (EAFUS) database, including the Food Chemical Codex.
In 2015, EFSA conducted a comprehensive assessment of the safety and health implications of using ascorbyl palmitate as an additive, concluding that it posed no threats to human health, including its use in infant food.
In a 2020 follow-up opinion, EFSA concluded that the current use of ascorbyl palmitate as a food additive in infant formula or in food for special medical purposes does also not raise safety concerns in this vulnerable population group.
The EFSA Panel considered that the toxicity of ascorbyl palmitate can be extrapolated from data describing the toxicity of ascorbic acid and palmitic acid, but the Panel concluded that the available toxicological data were too limited to establish a formal ADI for ascorbyl palmitate.
Acute Toxicity
Toxicity studies showed that the median lethal dose (LD50) of ascorbyl palmitate was in the range of 4,700 to more than 20,000 mg/kg body weight in mice, and 5,150 to more than 10,000 mg/kg body weight in rats.
These ingredients exhibit low acute oral toxicity in animals.
No reports of excessive levels of heavy metals or other dangerous contaminants in ascorbyl palmitate have been identified; no substances listed on FDA's Action Levels for Poisonous or Deleterious Substances in Human Food have been reported as contaminants of concern in ascorbyl palmitate.
Metabolite Safety
Based on in vitro data, the EFSA FAF Panel assumed that ascorbyl palmitate fully hydrolyses pre-systemically to ascorbic acid and palmitate. The Panel concluded that the intake of both metabolites at the maximum permitted levels for ascorbyl palmitate as a food additive in infant formula does not raise health concerns.
The EFSA ANS Panel also noted that the intake of palmitic acid from the use of ascorbyl palmitate as a food additive represents only a limited fraction (around 3%) of daily intake from the regular diet.
UVB / Keratinocyte Toxicity Concern (Topical Use)
A specific safety signal exists for topical dermal use in UV-exposed conditions. Two different studies found that ascorbyl palmitate did not protect mouse skin from UVB-induced photoaging and may also promote UVB-induced lipid peroxidation and cytotoxicity in human keratinocytes, which consequently exacerbates skin damage. This concern does not apply to oral or food additive use, and its clinical significance in humans at cosmetic-use concentrations remains unresolved.
Pro-Oxidant Potential in Iron-Replete States
Like ascorbic acid itself, ascorbyl palmitate carries a theoretical pro-oxidant risk in the presence of free transition metals, particularly iron, via Fenton-type chemistry. Ascorbic acid exhibits predominantly pro-oxidant activity by reducing Fe3+ to Fe2+, followed by the formation of dehydroascorbic acid; as a result, ascorbic acid accelerates the redox cycle Fe3+ ↔ Fe2+ in the Fenton reaction, which leads to a significant increase in the yield of toxic hydroxyl radicals. Whether this applies to ascorbyl palmitate after hydrolysis in the gut, or in intact form in lipid environments, has not been directly characterized in human clinical studies. However, data available do not indicate a significant increase in body iron stores with long-term ascorbic acid supplementation, suggesting the existence of a tightly regulated mechanism restricting iron absorption, which may limit the practical relevance of this concern at typical supplemental doses.
Skin Irritation
The Cosmetic Ingredient Review (CIR) Safety Assessment (Andersen, 1999) evaluated ascorbyl palmitate in cosmetic formulations. Human dermal irritation and sensitization studies submitted to the CIR showed no significant adverse skin reactions at typical cosmetic use concentrations. Ascorbyl palmitate is used in well over a thousand cosmetic formulations at low concentrations.
Data Gaps and Research Limitations
Biological data on ascorbyl palmitate are sparse relative to the breadth of proposed uses. Most mechanistic and efficacy research has been conducted in vitro or in animal models. The existing data about the applications of ascorbyl palmitate in promoting human health is still lacking. No large randomized controlled trials have been published examining ascorbyl palmitate as an oral supplement with defined clinical endpoints such as cardiovascular outcomes, inflammatory disease modification, or cancer prevention in humans.
References
Go back